SCHEMBL3012907

SCHEMBL3012907

O=S(=O)(c1ccccc1Br)N1CCN(c2nc(Cc3cc(F)cc(Cl)c3)cs2)CC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.44
KMT2A Q03164 3/20 0.44
LMNA P02545 3/20 0.44
MAPT P10636 3/20 0.44
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 2/20 0.44
GBA1 P04062 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
RAB9A P51151 1/20 0.39
PKM P14618 2/20 0.37
POLB P06746 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GPR183 P32249 1/20 0.37
MAPK1 P28482 2/20 0.37
USP2 O75604 1/20 0.37
RECQL P46063 1/20 0.37
HSD17B10 Q99714 1/20 0.37
EPHX2 P34913 1/20 0.36
HTR6 P50406 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017429 0.94 LMNA (0.48) SMN1; SMN2KMT2ALMNAMAPTALDH1A1
SCHEMBL3005316 0.94 GBA1 (0.42) SMN1; SMN2KMT2ALMNAMAPTALDH1A1
SCHEMBL3020813 0.92 KMT2A (0.46) SMN1; SMN2KMT2ALMNAMAPTALDH1A1
SCHEMBL2999233 0.88 SMN1; SMN2 (0.45) SMN1; SMN2KMT2ALMNAMAPTALDH1A1
SCHEMBL3012612 0.88 KMT2A (0.43) SMN1; SMN2KMT2ALMNAMAPTALDH1A1
SCHEMBL3016108 0.88 KMT2A (0.47) SMN1; SMN2KMT2ALMNAMAPTALDH1A1
SCHEMBL3008383 0.88 ALDH1A1 (0.39) SMN1; SMN2KMT2ALMNAMAPTALDH1A1
SCHEMBL3014105 0.87 ALDH1A1 (0.43) SMN1; SMN2KMT2ALMNAMAPTALDH1A1
SCHEMBL3005081 0.87 GBA1 (0.43) SMN1; SMN2KMT2ALMNAMAPTALDH1A1
SCHEMBL3018664 0.87 KMT2A (0.48) SMN1; SMN2KMT2ALMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885KMT2A 2680/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.